Inovio Pharmaceuticals Inc (INO): Next Thurs, 3rd GBM Drug Development Sum...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	13
Posts	3218
Boards Moderated	0
Alias Born	04/26/2007

Lakers_w

Re: None

Friday, 01/14/2022 3:36:33 PM

Friday, January 14, 2022 3:36:33 PM

Next Thurs, 3rd GBM Drug Development Summit. Boston, 1/20/2022, 8:30A EST
A Deep Dive into DNA Damage Repair for GBM
Jeffrey Skolnik
VP Clinical Development Inovio

Inovio’s DNA Medicine for the Treatment of Glioblastoma:
• Using novel DNA-encoded medicines to treat human cancers such as GBM
• Generating robust, specific anti-tumor T cells against GBM antigens
• Combining DNA medicine with immune checkpoint inhibitors to build clinical responses
• Inovio’s INO-5401 is a DNA medicine composed of plasmids that encode for the tumor associated antigens human telomerase (hTERT), Wilms tumor-1 (WT-1), and prostate-specific membrane antigen (PSMA); INO-9012 is a synthetic DNA plasmid that encodes for human IL-12 designed to stimulate T cells locally without a systemic effect
• Cemiplimab is a high-affinity, highly potent, human, hinge-stabilized IgG4 monoclonal antibody to the PD-1 receptor
https://glioblastoma-drugdevelopment.com/full-event-guide/